The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000666325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
24/04/2026
Date registered
Help: Date registered
4/06/2026
Date last updated
Help: Date last updated
4/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
4/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Using a Digital Menstrual Diary to Assess Health Literacy on Heavy Menstrual Bleeding (The MEASURE. Study)
Scientific title
Using a Digital Menstrual Diary to Assess Health Literacy in Adult Women with Heavy Menstrual Bleeding: A Feasibility Study
Additional trial identifiers [1] 317105 0
NA
Universal Trial Number (UTN)
Trial acronym
MEASURE.
Related trial records

Health condition
Health condition(s) studied:
Menorrhagia 341650 0
Heavy Menstrual Bleeding 341651 0
Condition category
Condition code
Reproductive Health and Childbirth 337741 337741 0 0
Menstruation and menopause

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants will receive a four-component intervention delivered alongside usual care over approximately 13–16 weeks (equivalent to three menstrual cycles). For the purposes of this study, usual care is defined as any healthcare or self-management participants would typically access independently, including general practitioner consultations, over-the-counter treatments, or specialist referrals, without direction from the research team.

The intervention comprises: (1) a digital menstrual diary completed via REDCap; (2) menstrual product use tracking (using either study-provided or participant-selected products); (3) access to evidence-based menstrual health education resources; and (4) a specialist medical consultation.

Participants will complete the digital menstrual diary daily during menstruation throughout the 12-week intervention period, capturing bleeding patterns, symptoms, quality of life impacts, and product/medication use. Validated measures embedded within REDCap include the Pictorial Blood Assessment Chart (PBAC), SAMANTA questionnaire, and Menstrual Bleeding Questionnaire (MBQ).

Participants will be given the option to use study-provided commercially available tampons and pads or their own preferred products, with product type and usage recorded to support interpretation of menstrual bleeding patterns.

Participants will receive access to curated, evidence-based menstrual health education resources delivered online. These resources are readily available (not developed specifically for this study) and include materials from reputable sources covering topics such as normal versus abnormal menstrual bleeding, recognition of heavy menstrual bleeding symptoms, when to seek medical care, self-management strategies, and understanding menstrual cycle physiology. Resources will be provided in multiple formats, including written information and web-based content, and participants will be encouraged to engage with these materials throughout the 12-week intervention period.

Following completion of the diary and education components, participants will attend a medical consultation at a specialist women’s health clinic (Women’s Health Road) within Weeks 13–16 of the study period for comprehensive assessment and clinical diagnosis by a gynaecologist. This will include review of medical history, symptom assessment, and where appropriate, pelvic ultrasound. If recent testing is unavailable, participants will be offered venous blood testing (full blood count and iron studies) to assess iron status in relation to menstrual bleeding.

Adherence to intervention components will be monitored via REDCap completion rates for the digital diary and questionnaires, and through tracking of engagement with educational resources where possible.
Intervention code [1] 333865 0
Diagnosis / Prognosis
Intervention code [2] 333866 0
Early detection / Screening
Description of the comparator or control
This study does not include a comparator or control group. It is a single-arm study in which all participants receive the multi-component intervention alongside usual care.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 345194 0
Acceptability (Composite)
Timepoint [1] 345194 0
Week 12-post enrolment
Primary outcome [2] 345300 0
Feasibility (Composite)
Timepoint [2] 345300 0
Week 12-post enrolment
Primary outcome [3] 345301 0
Safety (Composite)
Timepoint [3] 345301 0
Cycle 1 (Weeks 1 to 4), Cycle 2 (Weeks 5 to 8), and Cycle 3 (Weeks 9 to 12)
Secondary outcome [1] 460858 0
Preliminary Efficacy - Help Seeking
Timepoint [1] 460858 0
Week 12-post enrolment
Secondary outcome [2] 461210 0
Preliminary Efficacy - Self Management Strategies
Timepoint [2] 461210 0
Week 12-post enrolment
Secondary outcome [3] 461211 0
Preliminary Efficacy - Analgesic Medication
Timepoint [3] 461211 0
Week 12-post enrolment.
Secondary outcome [4] 461213 0
Preliminary Efficacy - Fatigue
Timepoint [4] 461213 0
Screening (Week 0); Week 12-post enrolment
Secondary outcome [5] 461214 0
Preliminary Efficacy - Health Literacy
Timepoint [5] 461214 0
Screening (Week 0); Week 12-post enrolment
Secondary outcome [6] 461215 0
Preliminary Efficacy - Perceived Control
Timepoint [6] 461215 0
Screening (Week 0); Week 12-post enrolment
Secondary outcome [7] 461216 0
Preliminary Efficacy - Health Economics
Timepoint [7] 461216 0
Screening (Week 0); Week 12 post-enrolment
Secondary outcome [8] 461217 0
Bleeding Patterns
Timepoint [8] 461217 0
Cycle 1 (Weeks 1 to 4), Cycle 2 (Weeks 5 to 8), Cycle 3 (Weeks 9 to 12)

Eligibility
Key inclusion criteria
Participants must meet all the following inclusion criteria prior to study entry to be eligible for enrolment:
• Aged 18 years or over
• Regular menstrual periods (21-34 days)
• Individuals who self-report symptoms consistent with possible heavy menstrual bleeding having one or more of the following symptoms: periods lasting more than 7 days, needing to change pads/tampons more frequently than every 2 hours, passing large clots, or experiencing significant disruption to daily activities but who have not received a formal clinical diagnosis of heavy menstrual bleeding.
• Able to use tampons and/or pads
• Willing to attend Women’s Health Road (WHR) for consultation
• Experienced menarche at least 12 months prior to recruitment
• Had at least 3 menstrual periods since menarche
• Willing to provide informed consent and adhere to protocol
• Access to smartphone, tablet, or computer with internet connectivity
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Healthy volunteers
No
Key exclusion criteria
Participants presenting with any of the following will be excluded from participating:
• Current pregnancy or breastfeeding
• Planning pregnancy during study period
• Current use of menstrual suppression therapy
• Significant cognitive impairment affecting ability to complete questionnaires
• Non-English speaking (insufficient English comprehension for questionnaire completion)

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Descriptive statistics will be used to summarise participant demographics, menstrual characteristics, and baseline measures, using appropriate measures of central tendency and variability. Feasibility and acceptability outcomes will be reported as proportions with 95% confidence intervals for categorical variables, and as means with standard deviations or medians with interquartile ranges for continuous variables. Preliminary efficacy outcomes will be assessed using pre–post comparisons, with paired t-tests for normally distributed data or non-parametric equivalents where appropriate, and effect sizes calculated to estimate the magnitude of change. Correlation analyses will be conducted to explore relationships between baseline characteristics, intervention engagement, clinical outcomes, and iron status in relation to bleeding patterns, using Pearson or Spearman correlation coefficients as appropriate.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW

Funding & Sponsors
Funding source category [1] 321688 0
Charities/Societies/Foundations
Name [1] 321688 0
Gates Foundation
Country [1] 321688 0
Australia
Primary sponsor type
University
Name
Western Sydney University
Address
Country
Australia
Secondary sponsor category [1] 324518 0
None
Name [1] 324518 0
Address [1] 324518 0
Country [1] 324518 0
Other collaborator category [1] 283918 0
Other
Name [1] 283918 0
Women's Health Road
Address [1] 283918 0
Country [1] 283918 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320224 0
University of Western Sydney Human Research Ethics Committee
Ethics committee address [1] 320224 0
Ethics committee country [1] 320224 0
Australia
Date submitted for ethics approval [1] 320224 0
24/11/2025
Approval date [1] 320224 0
24/02/2026
Ethics approval number [1] 320224 0
H17116

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149810 0
Prof Robert Gorkin III
Address 149810 0
Western Sydney University, Locked Bag 1797, Penrith NSW 2751
Country 149810 0
Australia
Phone 149810 0
+61 0401071021
Fax 149810 0
Email 149810 0
Contact person for public queries
Name 149811 0
Robert Gorkin III
Address 149811 0
Western Sydney University, Locked Bag 1797, Penrith NSW 2751
Country 149811 0
Australia
Phone 149811 0
+61 0401071021
Fax 149811 0
Email 149811 0
Contact person for scientific queries
Name 149812 0
Robert Gorkin III
Address 149812 0
Western Sydney University, Locked Bag 1797, Penrith NSW 2751
Country 149812 0
Australia
Phone 149812 0
+61 0401071021
Fax 149812 0
Email 149812 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.